Cancer Biomarker Testing Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012 to 2016 and Forecast 2017 to 2023
Cancer Biomarker Testing Market: Biomarker is any of body molecules that can be measured to assess the health. Molecules can be obtained from, body fluids, tissue or blood. Biomarker testing is also known as genetic testing or molecular testing. Biomarker test is a group of tests that look for these molecular signs of health so that doctors can plan best care. Cancer is referred as abnormal growth of the cells. Cancer biomarker is a process or substance that indicates the presence of cancer in the body. Genetic, epigenetic, glycemic, proteomic, and imaging biomarkers are used for cancer diagnosis, prognosis, and epidemiology. These cancer biomarkers used as risk indicators for various types of cancer such as lung cancer, breast cancer and prostate cancer among the others. Key cancer biomarkers include SCC, CEA, NSE Cyfra 21, PSA (prostate cancer), TPA (Lung cancer), CA15-3, EGF R, Cytokeratin 4 (breast cancer) and BRCA ½.
Cancer Biomarker Testing Market
The cancer biomarker test market is driven by rising prevalence of cancer worldwide. World Health Organization (WHO) stated that cancer is one of the leading causes of mortality and morbidity worldwide, with approximately 14 Mn new cases in 2012. The number of new cases is expected to rise about 70% over the coming 2 decades. In addition, increase in awareness in public and healthcare professionals regarding early diagnostic procedures, rise in government and NGO’s funding for oncology are expected to bolster the cancer biomarker testing market. Furthermore, the development of companion diagnostics and recent breakthrough in detection techniques such as proteomics, metabolomics, genomics and transcriptomics are further expected to boost the cancer biomarker test market. However, high cost for biomarker tests, low detection rates and regulatory policies are expected to hamper the cancer biomarker test market.
Cancer biomarker testing market segmented based on type of cancer, application, bio molecule and end user
Based on type of cancer, cancer biomarker test market is segmented into
Cervical cancer
Lung Cancer
Collateral Cancer
Liver Cancer
Prostate Cancer
Breast Cancer
Others
Based on application, cancer biomarker test market is segmented into
Drug Discovery and Development
Personalised Medicine
Diagnosis
Others
Based on end-user, cancer biomarker test market is segmented into
Hospitals
Cancer diagnostic Centres
Research Institutes
Others
The global cancer biomarker test market is expected to grow with significant CAGR during forecast period. Market players are carrying out collaborations, partnerships, and acquisitions as key development strategies to enhance the market share. For instance, in March 2017, Foundation Medicine and Bristol-Myers Squibb entered collaboration to understand tumour profile and its microenvironment to predict patient’s response to cancer immunotherapy. Using Foundation Medicine’s foundation genomic profiling assay, the firm will look at tumour mutational burden and microsatellite instability in patients enrolled in clinical trials for Bristol-Myers Squibb (BMS) cancer drugs. For instance, in October 2016, Arquer Diagnostics Ltd. (Arquer), and University of Sunderland are collaborated to investigate noninvasive specimen preparation techniques that will facilitate the use of Arquer’s MCM5-ELISA test in a wide range of cancers. In April 2016, Stemcentrix acquired by AbbiVe along with its lead late stage biomarker rovalpituzumab tesirine (Rova-T), that helps to identify tumour cells.
Geographically cancer biomarker testing market segmented into following regions viz. North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. North America is expected to be a major market for cancer biomarker test market owing to increase in research and development activities to diagnose and treating cancer and rise in prevalence of cancer. According to American Cancer Society (ACS), in 2017, it estimates 1,688,780 new cancer cases are diagnosed and 600,920 cancer deaths in the U.S. alone. Asia-Pacific region is expected to be fastest growing market due to increase in demand for the non-invasive techniques in diagnosis and prevention of cancer, high prevalence of cancer conditions in the region.
Some of the players in cancer biomarker test market are Thermo Fisher Scientific (Affymetrix Inc.) (U.S.), Abbott Laboratories (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), AbbVie Inc. (U.S.), Arquer Diagnostics Ltd. (U.K.), Illumina, Inc. (U.S.), Qiagen (Germany), Agilent Technologies (U.S.), Merck & Co. Inc. (U.S.), Becton Dickinson and Company (U.S.), and Hologic Inc. (U.S.) to name a few.
In 2015, Abbot Laboratories acquired exclusive rights for FGFR3 gene mutations to detect bladder cancer. FGFR3 developed at Institute Curie, it is a gene mutation and useful for early detection, disease monitoring, and prognosis of bladder cancer through tissue and urine-based testing
Cancer Biomarker Testing Market
The cancer biomarker test market is driven by rising prevalence of cancer worldwide. World Health Organization (WHO) stated that cancer is one of the leading causes of mortality and morbidity worldwide, with approximately 14 Mn new cases in 2012. The number of new cases is expected to rise about 70% over the coming 2 decades. In addition, increase in awareness in public and healthcare professionals regarding early diagnostic procedures, rise in government and NGO’s funding for oncology are expected to bolster the cancer biomarker testing market. Furthermore, the development of companion diagnostics and recent breakthrough in detection techniques such as proteomics, metabolomics, genomics and transcriptomics are further expected to boost the cancer biomarker test market. However, high cost for biomarker tests, low detection rates and regulatory policies are expected to hamper the cancer biomarker test market.
Cancer biomarker testing market segmented based on type of cancer, application, bio molecule and end user
Based on type of cancer, cancer biomarker test market is segmented into
Cervical cancer
Lung Cancer
Collateral Cancer
Liver Cancer
Prostate Cancer
Breast Cancer
Others
Based on application, cancer biomarker test market is segmented into
Drug Discovery and Development
Personalised Medicine
Diagnosis
Others
Based on end-user, cancer biomarker test market is segmented into
Hospitals
Cancer diagnostic Centres
Research Institutes
Others
The global cancer biomarker test market is expected to grow with significant CAGR during forecast period. Market players are carrying out collaborations, partnerships, and acquisitions as key development strategies to enhance the market share. For instance, in March 2017, Foundation Medicine and Bristol-Myers Squibb entered collaboration to understand tumour profile and its microenvironment to predict patient’s response to cancer immunotherapy. Using Foundation Medicine’s foundation genomic profiling assay, the firm will look at tumour mutational burden and microsatellite instability in patients enrolled in clinical trials for Bristol-Myers Squibb (BMS) cancer drugs. For instance, in October 2016, Arquer Diagnostics Ltd. (Arquer), and University of Sunderland are collaborated to investigate noninvasive specimen preparation techniques that will facilitate the use of Arquer’s MCM5-ELISA test in a wide range of cancers. In April 2016, Stemcentrix acquired by AbbiVe along with its lead late stage biomarker rovalpituzumab tesirine (Rova-T), that helps to identify tumour cells.
Geographically cancer biomarker testing market segmented into following regions viz. North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. North America is expected to be a major market for cancer biomarker test market owing to increase in research and development activities to diagnose and treating cancer and rise in prevalence of cancer. According to American Cancer Society (ACS), in 2017, it estimates 1,688,780 new cancer cases are diagnosed and 600,920 cancer deaths in the U.S. alone. Asia-Pacific region is expected to be fastest growing market due to increase in demand for the non-invasive techniques in diagnosis and prevention of cancer, high prevalence of cancer conditions in the region.
Some of the players in cancer biomarker test market are Thermo Fisher Scientific (Affymetrix Inc.) (U.S.), Abbott Laboratories (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), AbbVie Inc. (U.S.), Arquer Diagnostics Ltd. (U.K.), Illumina, Inc. (U.S.), Qiagen (Germany), Agilent Technologies (U.S.), Merck & Co. Inc. (U.S.), Becton Dickinson and Company (U.S.), and Hologic Inc. (U.S.) to name a few.
In 2015, Abbot Laboratories acquired exclusive rights for FGFR3 gene mutations to detect bladder cancer. FGFR3 developed at Institute Curie, it is a gene mutation and useful for early detection, disease monitoring, and prognosis of bladder cancer through tissue and urine-based testing
1. EXECUTIVE SUMMARY
2. GLOBAL CANCER BIOMARKER TESTING MARKET INTRODUCTION
2.1. Global Cancer Biomarker Testing Market – Taxonomy
2.2. Global Cancer Biomarker Testing Market –Definitions
2.2.1. Type of Cancer
2.2.2. Application
2.2.3. End User
3. GLOBAL CANCER BIOMARKER TESTING MARKET DYNAMICS
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Cancer Biomarker Testing Market Dynamic Factors - Impact Analysis
3.6. Global Cancer Biomarker Testing Market – Regulations
3.6.1. U.S.
3.6.2. Europe
3.7. Global Cancer Biomarker Testing Market –Trends
4. GLOBAL CANCER BIOMARKER TESTING MARKET ANALYSIS, 2012 – 2016 AND FORECAST, 2017 – 2023
4.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Opportunity Analysis
5. GLOBAL CANCER BIOMARKER TESTING MARKET , BY TYPE OF CANCER, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)
5.1. Cervical Cancer
5.1.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3. Market Opportunity Analysis
5.2. Lung Cancer
5.2.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
5.3. Collateral Cancer
5.3.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.3. Market Opportunity Analysis
5.4. Liver Cancer
5.4.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.4.3. Market Opportunity Analysis
5.5. Prostate Cancer
5.5.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.5.3. Market Opportunity Analysis
5.6. Breast Cancer
5.6.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.6.3. Market Opportunity Analysis
5.7. Others
5.7.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.7.3. Market Opportunity Analysis
6. GLOBAL CANCER BIOMARKER TESTING MARKET FORECAST, BY APPLICATION, 2012 - 2016 AND FORECAST, 2017 – 2023
6.1. Drug Discovery and Development
6.1.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Personalised Medicine
6.2.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
6.3. Diagnosis
6.3.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.3.3. Market Opportunity Analysis
6.4. Others
6.4.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.4.3. Market Opportunity Analysis
7. GLOBAL CANCER BIOMARKER TESTING MARKET FORECAST, BY END USER, 2012 - 2016 AND FORECAST, 2017 – 2023
7.1. Hospitals
7.1.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Cancer Diagnostic Centres
7.2.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
7.3. Research Institutes
7.3.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.3. Market Opportunity Analysis
7.4. Others
7.4.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.4.3. Market Opportunity Analysis
8. GLOBAL CANCER BIOMARKER TESTING MARKET FORECAST, BY REGION, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)
8.1. North America
8.1.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.1.3. Market Opportunity Analysis
8.2. Europe
8.2.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.2.3. Market Opportunity Analysis
8.3. Asia-Pacific
8.3.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.3.3. Market Opportunity Analysis
8.4. Latin America
8.4.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.4.3. Market Opportunity Analysis
8.5. Middle East and Africa
8.5.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.5.3. Market Opportunity Analysis
8.6. Global Cancer Biomarker Testing Market - Opportunity Analysis Index, By Type of Cancer, By Application, By End Use and Region, 2017 – 2023
9. NORTH AMERICA CANCER BIOMARKER TESTING MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)
9.1. Type of Cancer Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.1.1. Cervical cancer
9.1.2. Lung Cancer
9.1.3. Collateral Cancer
9.1.4. Liver Cancer
9.1.5. Prostate Cancer
9.1.6. Breast Cancer
9.1.7. Others
9.2. Application Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
9.2.1. Drug Discovery and Development
9.2.2. Personalised Medicine
9.2.3. Diagnosis
9.2.4. Others
9.3. End User Type Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
9.3.1. Hospitals
9.3.2. Cancer Diagnostic Centres
9.3.3. Research Institutes
9.3.4. Others
9.4. Country Analysis 2016 and Forecast 2017 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
9.4.1. U.S.
9.4.2. Canada
9.5. North America Cancer Biomarker Testing Market - Opportunity Analysis Index, By Type of Cancer, By Application, By End Use and Country, 2017 – 2023
9.6. North America Cancer Biomarker Testing Market Dynamics – Trends
10. EUROPE CANCER BIOMARKER TESTING MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)
10.1. Type of Cancer Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.1.1. Cervical cancer
10.1.2. Lung Cancer
10.1.3. Collateral Cancer
10.1.4. Liver Cancer
10.1.5. Prostate Cancer
10.1.6. Breast Cancer
10.1.7. Others
10.2. Application Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.2.1. Drug Discovery and Development
10.2.2. Personalised Medicine
10.2.3. Diagnosis
10.2.4. Others
10.3. End User Type Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.3.1. Hospitals
10.3.2. Cancer Diagnostic Centres
10.3.3. Research Institutes
10.3.4. Others
10.4. Country Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
10.4.1. Germany
10.4.2. UK
10.4.3. France
10.4.4. Spain
10.4.5. Italy
10.4.6. Russia
10.4.7. Poland
10.4.8. Rest of Europe
10.5. Europe Cancer Biomarker Testing Market - Opportunity Analysis Index, By Type of Cancer, By Application, By End Use and Country, 2017 – 2023
10.6. Europe Cancer Biomarker Testing Market Dynamics – Trends
11. ASIA-PACIFIC CANCER BIOMARKER TESTING MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)
11.1. Type of Cancer Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.1.1. Cervical cancer
11.1.2. Lung Cancer
11.1.3. Collateral Cancer
11.1.4. Liver Cancer
11.1.5. Prostate Cancer
11.1.6. Breast Cancer
11.1.7. Others
11.2. Application Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.2.1. Drug Discovery and Development
11.2.2. Personalised Medicine
11.2.3. Diagnosis
11.2.4. Others
11.3. End User Type Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.3.1. Hospitals
11.3.2. Cancer Diagnostic Centres
11.3.3. Research Institutes
11.3.4. Others
11.4. Country Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
11.4.1. Japan
11.4.2. China
11.4.3. India
11.4.4. ASEAN
11.4.5. Australia & New Zealand
11.4.6. Rest of Asia-Pacific
11.5. Asia-Pacific Cancer Biomarker Testing Market - Opportunity Analysis Index, By Type of Cancer, By Application, By End Use and Country, 2017 – 2023
11.6. Asia-Pacific Cancer Biomarker Testing Market Dynamics – Trends
12. LATIN AMERICA CANCER BIOMARKER TESTING MARKET ANALYSIS, 2012 - 2012 - 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)
12.1. Type of Cancer Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.1. Cervical cancer
12.1.2. Lung Cancer
12.1.3. Collateral Cancer
12.1.4. Liver Cancer
12.1.5. Prostate Cancer
12.1.6. Breast Cancer
12.1.7. Others
12.2. Application Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.2.1. Drug Discovery and Development
12.2.2. Personalised Medicine
12.2.3. Diagnosis
12.2.4. Others
12.3. End User Type Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.3.1. Hospitals
12.3.2. Cancer Diagnostic Centres
12.3.3. Research Institutes
12.3.4. Others
12.4. Country Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Argentina
12.4.4. Venezuela
12.4.5. Rest of Latin America
12.5. Latin America Cancer Biomarker Testing Market - Opportunity Analysis Index, By Type of Cancer, By Application, By End Use and Country, 2017 – 2023
12.6. Latin America Cancer Biomarker Testing Market Dynamics – Trends
13. MIDDLE EAST AND AFRICA CANCER BIOMARKER TESTING MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)
13.1. Type of Cancer Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.1.1. Cervical cancer
13.1.2. Lung Cancer
13.1.3. Collateral Cancer
13.1.4. Liver Cancer
13.1.5. Prostate Cancer
13.1.6. Breast Cancer
13.1.7. Others
13.2. Application Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.2.1. Drug Discovery and Development
13.2.2. Personalised Medicine
13.2.3. Diagnosis
13.2.4. Others
13.3. End User Type Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.3.1. Hospitals
13.3.2. Cancer Diagnostic Centres
13.3.3. Research Institutes
13.3.4. Others
13.4. Country Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
13.4.1. Gulf Cooperation Council (GCC) Countries
13.4.2. Israel
13.4.3. South Africa
13.4.4. Rest of MEA
13.5. MEA Cancer Biomarker Testing Market - Opportunity Analysis Index, By Type of Cancer, By Application, By End Use and Country, 2017 – 2023
13.6. MEA Cancer Biomarker Testing Market Dynamics – Trends
14. COMPETITION LANDSCAPE
14.1. Strategic Dashboard of Top Market Players
14.2. Company Profiles (Introduction, Financial Analysis, Product & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
14.2.1. Thermo Fisher Scientific (Affymetrix Inc.) (U.S.)
14.2.2. Abbott Laboratories (U.S.)
14.2.3. F. Hoffmann-La Roche Ltd. (Switzerland)
14.2.4. AbbVie Inc. (U.S.)
14.2.5. Arquer Diagnostics Ltd. (U.K.)
14.2.6. Illumina, Inc. (U.S.)
14.2.7. Qiagen (Germany)
14.2.8. Agilent Technologies (U.S.)
14.2.9. Merck & Co. Inc. (U.S.)
14.2.10. Becton Dickinson and Company (U.S.)
14.2.11. Hologic Inc. (U.S.)
15. RESEARCH METHODOLOGY
16. KEY ASSUMPTIONS AND ACRONYMS
2. GLOBAL CANCER BIOMARKER TESTING MARKET INTRODUCTION
2.1. Global Cancer Biomarker Testing Market – Taxonomy
2.2. Global Cancer Biomarker Testing Market –Definitions
2.2.1. Type of Cancer
2.2.2. Application
2.2.3. End User
3. GLOBAL CANCER BIOMARKER TESTING MARKET DYNAMICS
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Cancer Biomarker Testing Market Dynamic Factors - Impact Analysis
3.6. Global Cancer Biomarker Testing Market – Regulations
3.6.1. U.S.
3.6.2. Europe
3.7. Global Cancer Biomarker Testing Market –Trends
4. GLOBAL CANCER BIOMARKER TESTING MARKET ANALYSIS, 2012 – 2016 AND FORECAST, 2017 – 2023
4.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Opportunity Analysis
5. GLOBAL CANCER BIOMARKER TESTING MARKET , BY TYPE OF CANCER, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)
5.1. Cervical Cancer
5.1.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3. Market Opportunity Analysis
5.2. Lung Cancer
5.2.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
5.3. Collateral Cancer
5.3.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.3. Market Opportunity Analysis
5.4. Liver Cancer
5.4.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.4.3. Market Opportunity Analysis
5.5. Prostate Cancer
5.5.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.5.3. Market Opportunity Analysis
5.6. Breast Cancer
5.6.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.6.3. Market Opportunity Analysis
5.7. Others
5.7.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.7.3. Market Opportunity Analysis
6. GLOBAL CANCER BIOMARKER TESTING MARKET FORECAST, BY APPLICATION, 2012 - 2016 AND FORECAST, 2017 – 2023
6.1. Drug Discovery and Development
6.1.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Personalised Medicine
6.2.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
6.3. Diagnosis
6.3.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.3.3. Market Opportunity Analysis
6.4. Others
6.4.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.4.3. Market Opportunity Analysis
7. GLOBAL CANCER BIOMARKER TESTING MARKET FORECAST, BY END USER, 2012 - 2016 AND FORECAST, 2017 – 2023
7.1. Hospitals
7.1.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Cancer Diagnostic Centres
7.2.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
7.3. Research Institutes
7.3.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.3. Market Opportunity Analysis
7.4. Others
7.4.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.4.3. Market Opportunity Analysis
8. GLOBAL CANCER BIOMARKER TESTING MARKET FORECAST, BY REGION, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)
8.1. North America
8.1.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.1.3. Market Opportunity Analysis
8.2. Europe
8.2.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.2.3. Market Opportunity Analysis
8.3. Asia-Pacific
8.3.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.3.3. Market Opportunity Analysis
8.4. Latin America
8.4.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.4.3. Market Opportunity Analysis
8.5. Middle East and Africa
8.5.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.5.3. Market Opportunity Analysis
8.6. Global Cancer Biomarker Testing Market - Opportunity Analysis Index, By Type of Cancer, By Application, By End Use and Region, 2017 – 2023
9. NORTH AMERICA CANCER BIOMARKER TESTING MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)
9.1. Type of Cancer Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.1.1. Cervical cancer
9.1.2. Lung Cancer
9.1.3. Collateral Cancer
9.1.4. Liver Cancer
9.1.5. Prostate Cancer
9.1.6. Breast Cancer
9.1.7. Others
9.2. Application Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
9.2.1. Drug Discovery and Development
9.2.2. Personalised Medicine
9.2.3. Diagnosis
9.2.4. Others
9.3. End User Type Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
9.3.1. Hospitals
9.3.2. Cancer Diagnostic Centres
9.3.3. Research Institutes
9.3.4. Others
9.4. Country Analysis 2016 and Forecast 2017 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
9.4.1. U.S.
9.4.2. Canada
9.5. North America Cancer Biomarker Testing Market - Opportunity Analysis Index, By Type of Cancer, By Application, By End Use and Country, 2017 – 2023
9.6. North America Cancer Biomarker Testing Market Dynamics – Trends
10. EUROPE CANCER BIOMARKER TESTING MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)
10.1. Type of Cancer Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.1.1. Cervical cancer
10.1.2. Lung Cancer
10.1.3. Collateral Cancer
10.1.4. Liver Cancer
10.1.5. Prostate Cancer
10.1.6. Breast Cancer
10.1.7. Others
10.2. Application Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.2.1. Drug Discovery and Development
10.2.2. Personalised Medicine
10.2.3. Diagnosis
10.2.4. Others
10.3. End User Type Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.3.1. Hospitals
10.3.2. Cancer Diagnostic Centres
10.3.3. Research Institutes
10.3.4. Others
10.4. Country Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
10.4.1. Germany
10.4.2. UK
10.4.3. France
10.4.4. Spain
10.4.5. Italy
10.4.6. Russia
10.4.7. Poland
10.4.8. Rest of Europe
10.5. Europe Cancer Biomarker Testing Market - Opportunity Analysis Index, By Type of Cancer, By Application, By End Use and Country, 2017 – 2023
10.6. Europe Cancer Biomarker Testing Market Dynamics – Trends
11. ASIA-PACIFIC CANCER BIOMARKER TESTING MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)
11.1. Type of Cancer Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.1.1. Cervical cancer
11.1.2. Lung Cancer
11.1.3. Collateral Cancer
11.1.4. Liver Cancer
11.1.5. Prostate Cancer
11.1.6. Breast Cancer
11.1.7. Others
11.2. Application Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.2.1. Drug Discovery and Development
11.2.2. Personalised Medicine
11.2.3. Diagnosis
11.2.4. Others
11.3. End User Type Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.3.1. Hospitals
11.3.2. Cancer Diagnostic Centres
11.3.3. Research Institutes
11.3.4. Others
11.4. Country Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
11.4.1. Japan
11.4.2. China
11.4.3. India
11.4.4. ASEAN
11.4.5. Australia & New Zealand
11.4.6. Rest of Asia-Pacific
11.5. Asia-Pacific Cancer Biomarker Testing Market - Opportunity Analysis Index, By Type of Cancer, By Application, By End Use and Country, 2017 – 2023
11.6. Asia-Pacific Cancer Biomarker Testing Market Dynamics – Trends
12. LATIN AMERICA CANCER BIOMARKER TESTING MARKET ANALYSIS, 2012 - 2012 - 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)
12.1. Type of Cancer Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.1. Cervical cancer
12.1.2. Lung Cancer
12.1.3. Collateral Cancer
12.1.4. Liver Cancer
12.1.5. Prostate Cancer
12.1.6. Breast Cancer
12.1.7. Others
12.2. Application Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.2.1. Drug Discovery and Development
12.2.2. Personalised Medicine
12.2.3. Diagnosis
12.2.4. Others
12.3. End User Type Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.3.1. Hospitals
12.3.2. Cancer Diagnostic Centres
12.3.3. Research Institutes
12.3.4. Others
12.4. Country Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Argentina
12.4.4. Venezuela
12.4.5. Rest of Latin America
12.5. Latin America Cancer Biomarker Testing Market - Opportunity Analysis Index, By Type of Cancer, By Application, By End Use and Country, 2017 – 2023
12.6. Latin America Cancer Biomarker Testing Market Dynamics – Trends
13. MIDDLE EAST AND AFRICA CANCER BIOMARKER TESTING MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)
13.1. Type of Cancer Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.1.1. Cervical cancer
13.1.2. Lung Cancer
13.1.3. Collateral Cancer
13.1.4. Liver Cancer
13.1.5. Prostate Cancer
13.1.6. Breast Cancer
13.1.7. Others
13.2. Application Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.2.1. Drug Discovery and Development
13.2.2. Personalised Medicine
13.2.3. Diagnosis
13.2.4. Others
13.3. End User Type Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.3.1. Hospitals
13.3.2. Cancer Diagnostic Centres
13.3.3. Research Institutes
13.3.4. Others
13.4. Country Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
13.4.1. Gulf Cooperation Council (GCC) Countries
13.4.2. Israel
13.4.3. South Africa
13.4.4. Rest of MEA
13.5. MEA Cancer Biomarker Testing Market - Opportunity Analysis Index, By Type of Cancer, By Application, By End Use and Country, 2017 – 2023
13.6. MEA Cancer Biomarker Testing Market Dynamics – Trends
14. COMPETITION LANDSCAPE
14.1. Strategic Dashboard of Top Market Players
14.2. Company Profiles (Introduction, Financial Analysis, Product & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
14.2.1. Thermo Fisher Scientific (Affymetrix Inc.) (U.S.)
14.2.2. Abbott Laboratories (U.S.)
14.2.3. F. Hoffmann-La Roche Ltd. (Switzerland)
14.2.4. AbbVie Inc. (U.S.)
14.2.5. Arquer Diagnostics Ltd. (U.K.)
14.2.6. Illumina, Inc. (U.S.)
14.2.7. Qiagen (Germany)
14.2.8. Agilent Technologies (U.S.)
14.2.9. Merck & Co. Inc. (U.S.)
14.2.10. Becton Dickinson and Company (U.S.)
14.2.11. Hologic Inc. (U.S.)
15. RESEARCH METHODOLOGY
16. KEY ASSUMPTIONS AND ACRONYMS
